PT-141 shots are injectable bremelanotide, an FDA-approved prescription for low sexual desire in premenopausal women. Learn how they work and the risks.
PT-141 shots are subcutaneous injections of bremelanotide, a prescription medication the FDA approved in 2019 under the brand name Vyleesi. Doctors prescribe them to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. A PT-141 shot is not a general libido booster, not a hormone, and not an FDA-approved treatment for erectile dysfunction.
The active ingredient is a synthetic peptide that acts on receptors in the brain rather than on blood vessels or testosterone. That distinction matters, because it explains both what the drug can do and why it carries such a narrow set of approved uses.
What PT-141 Is and Where It Came From
If you have ever typed what is pt-141 into a search bar, you were probably trying to separate the hype from the pharmacology. The short answer: it is a melanocortin receptor agonist derived from research into melanotan II, a peptide originally studied for its tanning effects.
Researchers noticed that melanotan II produced unexpected sexual side effects in early trials, and they isolated a metabolite with a stronger effect on desire. That compound became bremelanotide, also known as PT-141.
So, is bremelanotide the same as pt 141? Yes. The two names describe the identical molecule. Vyleesi is simply the brand name of the FDA-approved injectable version.
How PT-141 Shots Work in the Body
Bremelanotide binds to melanocortin receptors, especially MC4R, in the hypothalamus — a region of the brain involved in appetite, arousal, and reward signaling. Activating those receptors appears to influence sexual desire at the central nervous system level.
It does not work like a PDE5 inhibitor. PT-141 does not widen blood vessels in the penis, and it does not raise testosterone. That is why it is not an erection drug and why it is not a substitute for hormone therapy.
- Onset: typically within 45 minutes to a few hours after injection.
- Duration: effects generally fade over several hours.
- Frequency: taken on demand, not daily.
Who PT-141 Shots Are Approved For
The FDA label is specific. Vyleesi is approved for premenopausal women with acquired, generalized HSDD — meaning low desire that developed over time rather than existing for life, and that occurs across situations rather than only with one partner.
PT-141 is not FDA-approved for men, and it is not approved for postmenopausal women, though researchers have studied both groups. If you are asking what is pt 141 good for, the honest answer is a narrow, well-defined diagnosis in a specific population.
Dosing and How a Shot Is Given
The approved dose is 1.75 mg injected subcutaneously into the abdomen or thigh, at least 45 minutes before anticipated sexual activity. Users should not exceed one dose in 24 hours or more than eight doses in a month.
The product comes as a single-use autoinjector, which makes self-administration fairly straightforward. Rotating injection sites helps reduce local irritation.
Because it is taken on demand, timing matters more than a fixed schedule. Your prescriber can explain what is pt 141 used for in your specific situation and whether an on-demand pattern fits your needs.
PT-141 Injection vs. Nasal Spray vs. Compounded Vials
| Form | Regulatory status | Typical use | Key concerns |
|---|---|---|---|
| Vyleesi autoinjector (bremelanotide) | FDA-approved | HSDD in premenopausal women | Nausea, blood pressure changes, prescription required |
| Compounded PT-141 injection | Not FDA-approved | Off-label, often marketed to men | Variable purity, dosing errors, no safety oversight |
| PT-141 nasal spray | Not FDA-approved | Research use only | Inconsistent absorption, abandoned in early development |
An earlier nasal formulation was discontinued during development because absorption was inconsistent and blood pressure effects were hard to manage. That history is worth knowing for anyone asking what is pt 141 nasal spray is and why it mostly shows up on research chemical sites.
Side Effects and Safety Considerations
Nausea is the most common side effect, reported by roughly 40% of participants in clinical trials. Flushing, headache, vomiting, and injection site reactions are also common.
Bremelanotide can raise blood pressure and temporarily lower heart rate. It is contraindicated in people with uncontrolled hypertension or known cardiovascular disease.
Other reported effects include darkening of the skin, gums, or face with repeated use, along with rare cases of focal hyperpigmentation. PT-141 is not recommended during pregnancy, and it is banned by the World Anti-Doping Agency for athletes in competition.
Anyone with a heart condition, taking blood pressure medication, or using naltrexone should talk with a clinician first. This article is informational and is not a substitute for medical advice.
Cost, Legality, and Buying Online
Vyleesi is prescription-only in the United States. List pricing has been high — historically more than $1,000 per month without insurance — though manufacturer copay programs and some commercial plans reduce the cost.
Compounded and "research grade" PT-141 sold online is a different category entirely. Those vials are not FDA-approved, are not produced under pharmaceutical manufacturing standards, and are frequently labeled "not for human consumption."
Buying from an unregulated vendor means no guarantee of sterility, concentration, or identity of the peptide. Injected products carry added risk when quality control is absent, including infection and dosing errors.
What to Discuss With a Healthcare Professional
- Whether your symptoms match the approved diagnosis for HSDD.
- Your blood pressure and cardiovascular history.
- Other medications, especially antihypertensives and naltrexone.
- Realistic expectations about how well the drug works.
Clinical trials showed modest average improvements in desire and related distress, with many participants reporting little change. PT-141 shots are one option among several for low sexual desire, and they are not a guaranteed fix.
Frequently Asked Questions
What is PT-141 used for?
PT-141 (bremelanotide) is FDA-approved to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is used on demand, about 45 minutes before sexual activity, rather than as a daily medication. It is not approved for men or for erectile dysfunction.
Is bremelanotide the same as PT-141?
Yes. Bremelanotide is the generic drug name and PT-141 is the research name for the same molecule. Vyleesi is the brand-name autoinjector the FDA approved in 2019.
How long does a PT-141 shot take to work?
Users are instructed to inject at least 45 minutes before sexual activity, and effects typically appear within one to two hours. The effect fades over several hours. Doses should not be repeated within a 24-hour period.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.